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Edited by Horst FeldmannAbstract Non-steroidal anti-inﬂammatory drugs (NSAIDs),
such as indomethacin, have serious gastrointestinal side eﬀects.
Since their direct cytotoxicity was suggested to be involved in
this side eﬀect, we here tried to identify NSAID-resistant genes.
We screened for Saccharomyces cerevisiae genes whose overex-
pression causes indomethacin resistance and identiﬁed the TPO1
gene, which encodes a major facilitator superfamily transporter.
Its overexpression or deletion made yeast cells resistant or sensi-
tive, respectively, to some NSAIDs. A BLAST search identiﬁed
the possible human orthologue of Tpo1p, tetracycline trans-
porter-like protein (TETRAN), whose overexpression in cultured
human cells caused resistance to some NSAIDs, suggesting that
TETRAN is an eﬄux pump for some NSAIDs.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Non-steroidal anti-inﬂammatory drugs (NSAIDs) are some
of the most frequently used medicines in the world and ac-
count for nearly 5% of all prescribed medications [1]. However,
NSAIDs frequently have side eﬀects, including gastrointestinal
ulcers and bleeding [2]. Individual variation of sensitivity is a
serious clinical problem, but the genetic factors determining
this variation are unknown.
Inhibition of cyclooxygenase (COX) by NSAIDs, which is
responsible for their anti-inﬂammatory activity, was previously
thought to be fully responsible for their gastrointestinal side ef-
fects [3]. However, the increased incidence of gastrointestinal
ulcers and the decrease in prostaglandin (PG) levels inducedAbbreviations: ABC, ATP binding cassette; COX, cyclooxygenase;
Drtet, D. melanogaster tetracycline resistance protein; FBS, fetal
bovine serum; MFS, major facilitator superfamily; MTT, 3-(4,5-
dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NSAID,
non-steroidal anti-inﬂammatory drug; OD, optical density; PG,
prostaglandin; SC, synthetic complete; SNP, single nucleotide
polymorphism; TETRAN, tetracycline transporter-like protein
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doi:10.1016/j.febslet.2007.03.001by NSAIDs are not always linked, suggesting that additional
mechanisms could be implicated [4]. We recently showed that
these involve the direct cytotoxic activity of NSAIDs that is
independent on their COX-inhibition activity [5]. Therefore,
genes that aﬀect this cytotoxicity may determine risk of gastric
lesions, but such genes have not been identiﬁed.
For identifying genes that aﬀect the cytotoxicity, we screened
Saccharomyces cerevisiae genes whose overexpression confers
resistance to indomethacin, and we thus identiﬁed TPO1,
which belongs to the major facilitator superfamily (MFS) of
transporters. By a BLAST search, we identiﬁed a possible
human orthologue, tetracycline transporter-like protein (TET-
RAN), which is predicted to be a drug transporter because of
its strong amino acid sequence similarity to a tetracycline
transporter in E. coli [6]. When TETRAN was overexpressed
in cultured human cells, cells became resistant to some NSA-
IDs. We therefore consider that TETRAN is probably respon-
sible for the eﬄux of NSAIDs from cells.2. Materials and methods
2.1. Plasmids and yeast strains
The tpo mutants and the parent strain (YPH499) were kindly do-
nated by Dr. K. Igarashi (Chiba University) [7].
A plasmid containing cDNA for the human TETRAN gene was ob-
tained from Invitrogen. After digestion by EcoRI and XhoI, the resul-
tant DNA fragment was inserted into the EcoRI–XhoI site of
pcDNA3.1(+) to obtain the expression plasmid for TETRAN. Trans-
fection of the plasmid was carried out using Lipofectamine (TM2000)
or HilyMax according to the manufacturer’s protocol. Transfection of
siRNA was performed by HiPerFect transfection reagent according to
the manufacturer’s instructions. Real-time RT-PCR analysis was done
as described [8].2.2. Preparation of yeast genomic library and screening of
indomethacin-resistant transformants
Total chromosomal DNA from yeast W303-1 cells was partially
digested by Sau3AI. DNA fragments (4–10 kb) were puriﬁed by
ultra-centrifugation in the presence of CsCl, and ligated into the
BamHI site of pYES2 (Invitrogen). The resultant yeast genomic library
was introduced into W303-1 cells and indomethacin-resistant transfor-
mants were selected on synthetic complete (SC) agar plates containing
0.6 mM indomethacin.2.3. Northern blotting
Total RNA was extracted from yeast or human cells by use of an
RNeasy kit, according to the manufacturer’s speciﬁcations. Samples
were separated by agarose gel electrophoresis in the presence of 6.3%blished by Elsevier B.V. All rights reserved.
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ence). Partial DNA fragments of TPO1 were ampliﬁed by PCR as de-
scribed [9] and partial DNA fragments of TETRAN were produced by
digesting the full-length cDNA with NdeI and Aor51HI. These were
radioactively labeled and used as probes.
2.4. Assay for sensitivity of cells to NSAIDs
Cells were cultured in RPMI1640 medium containing 10% fetal
bovine serum. Cell viability as determined by the 3-(4,5-dimethyl-thia-A
B
C
D
Fig. 1. Identiﬁcation in yeast of the TPO1 gene, which caused resistance
derivatives (X, XbaI; B, BalI; P, PvuII; K, KpnI). The GAL promoter of pYES
each plasmid were streaked on SC agar plates containing 0 or 0.6 mM indom
harboring pHW96, pHW99 or the vector (pYES2) were streaked on SC aga
plates were incubated for 4 days. (D) A full growth suspension of W303-1
appropriately and streaked on SC agar plates containing the indicated conce
were counted and colony-forming units (colonies formed per 1 ml full growtzol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method [10]. Apop-
totic chromatin condensation was observed as described [10].2.5. Statistical analysis
Values are expressed as a means ± standard error (S.E.M.). One-way
analysis of variance (ANOVA) followed by Scheﬀe’s multiple compar-
ison was used to evaluate diﬀerences between groups. Results were
considered to be signiﬁcant for values of P < 0.05.to indomethacin. (A) Restriction enzyme maps for pHW96 and its
2 is located on the right side of each insert. (B) W303-1 cells harboring
ethacin and plates were incubated at 30 C for 4 days. (C) W303-1 cells
r plates containing the indicated concentrations of indomethacin, and
harboring pHW99 (closed circle) or pYES2 (open circle) was diluted
ntrations of indomethacin. Plates were incubated for 4 days. Colonies
h suspension) were determined.
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3.1. Screening for indomethacin-resistance genes in yeast
DNA fragments prepared from chromosomes of S. cerevi-
siae W303-1 cells were introduced into pYES2, under the con-
trol of the GAL promoter. After transformation of W303-1
cells with this DNA library, we identiﬁed 18 independent indo-
methacin resistant colonies from about 20000 transformants
on SC agar plates containing 0.6 mM indomethacin. A plas-
mid from one of clones that were positive after re-transforma-
tion experiments (17 clones) was subjected to direct DNA
sequencing. The plasmid (pHW96) has two complete genes,
TPO1 and ISA1, and a fragment of HSP104 (Fig. 1A). Sub-
cloning revealed that TPO1 is responsible for resistance; a
plasmid, which contained only TPO1 (pHW99) made cells
resistant to indomethacin and deletion of TPO1 from
pHW96 (pHW97 and pHW98) diminished the resistance
(Fig. 1B). Plasmid from other 16 positive clones also contained
TPO1.
Further analysis was preformed using cells overexpressing
TPO1. While W303-1/pYES2 did not signiﬁcantly grow on
SC agar plates containing 0.3 mM indomethacin, W303-1/
pHW96 and W303-1/pHW99 could grow in the presence of
1.2 mM indomethacin (Fig. 1C). We also found that transfor-
mation of W303-1 with pHW99 dramatically increased its abil-
ity to form colonies in the presence of 0.3 – 1.2 mM
indomethacin (Fig. 1D). Furthermore, we draw growth curve
in the presence of various concentrations of indomethacin.
While W303-1/pYES2 could not grow in liquid medium con-
taining 0.3 mM indomethacin, W303-1/pHW99 could grow
in the presence of 1.2 mM indomethacin (Fig. 2). These results
indicate that cells harboring pHW99 are resistant to indometh-
acin.Fig. 2. Growth of yeast cells overexpressing TPO1 in the presence of NSAID
1/50 diluted and cultured at 30 C in the presence of 0 (open square), 0
indomethacin; 0 (open square), 0.1 (open diamond), 0.2 (closed circle), and 0.
0.2 (closed circle), and 0.4 (open triangle) mM ibuprofen; 0 (open square), 1 (
10 (closed square) mM aspirin. The optical density (OD) at 650 nm was moW303-1/pYES2 did not grow in liquid medium containing
0.1 mM diclofenac, but W303-1/pHW99 could grow in liquid
medium containing 0.2 mM diclofenac. In the presence of ibu-
profen, a little diﬀerence in growth was also seen, suggesting
that the resistance is not speciﬁc for indomethacin. On the
other hand, in the presence of aspirin, there was no clear dif-
ference in growth, showing that W303-1/pHW99 is not resis-
tant to all NSAIDs (Fig. 2).3.2. Sensitivity of tpo mutants to indomethacin
Results described above suggest that Tpo1p protects yeast
cells from NSAIDs. To further test this hypothesis, we exam-
ined a tpo1 disruption mutant, DTPO1. As shown in Fig. 3, the
wild-type strain could grow in liquid medium containing
0.2 mM indomethacin, but DTPO1 mutant did not grow in
liquid medium containing 0.1 mM indomethacin, again show-
ing that Tpo1p is involved in indomethacin-resistance in wild-
type yeast cells.
Recently, homologues of TPO1 (TPO2, TPO3 and TPO4)
were identiﬁed in S. cerevisiae, all involved in polyamine trans-
port and resistance to polyamines [7]. We examined their con-
tribution to indomethacin resistance, by use of disruption
mutants (DTPO2, DTPO3 and DTPO4). As shown in Fig. 3,
all mutants (DTPO2, DTPO3 and DTPO4) showed indometh-
acin-sensitivity similar to that of the wild-type strain. This sug-
gests that indomethacin resistance speciﬁcally involves Tpo1p,
whereas polyamine resistance involves several genes.3.3. Induction of TPO1 mRNA by indomethacin
Since herbicides induce the transcription of TPO1 [9], we
tested by Northern blotting analysis whether indomethacin
also induces the transcription of TPO1. As shown in Fig. 4,s. Full growth suspensions of W303-1/pHW99 or W303-1/pYES2 were
.3 (open diamond), 0.6 (closed circle), and 1.2 (open triangle) mM
4 (open triangle) mM diclofenac; 0 (open square), 0.1 (open diamond),
open diamond), 2 (closed circle), 4 (open triangle), 8 (open circle), and
nitored.
Fig. 3. Growth of yeast tpo mutants in the presence of indomethacin.
Full growth suspensions of DTPO1, DTPO2, DTPO3, DTPO4 and the
wild-type strain, YPH499, were 1/50 diluted and cultured at 30 C in
the presence of 0 (open square), 0.05 (open diamond), 0.1 (closed
circle), 0.15 (open triangle) and 0.2 (closed square) mM indomethacin.
The OD at 650 nm was monitored.
A
B
C
Fig. 4. Induction of TPO1 mRNA by indomethacin. Exponentially
growing W303-1 cells were (A) treated with 0.1 mM indomethacin for
the indicated periods or (B) with the indicated concentrations of
indomethacin for 3 h. MKN45 ells were exposed to various concen-
trations of indomethacin for 24 h (C). The level of TPO1 mRNA (A,
B) or TETRAN mRNA (C) was monitored by northern blotting
analysis. Lower panel shows ribosomal RNA (26S or 28S) stained with
ethidium bromide.
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TPO1 probably contributed to the protection of yeast cells
from indomethacin.
3.4. Identiﬁcation of the human orthologue of TPO1
A direct BLAST search of the human genome, using the
amino acid sequence of yeast Tpo1p as a query, did not ﬁnd
any matching genes. We therefore searched for the D. melano-
gaster orthologue of Tpo1p in a similar way and identiﬁed the
tetracycline resistance protein (Drtet; AE003733 [GenBank]),
which is predicted to be tetracycline eﬄux pump, based on
its amino acid sequence (information from GenBank home-
page). Drtet shows 8% identity and 25% similarity to yeast
Tpo1p in total. Finally, we identiﬁed a human orthologue of
Drtet, TETRAN (L11669 [GenBank]) [6]. TETRAN shows
40% identity and 74% similarity to Drtet in total. TETRAN
has putative 12-membrane-spanning domains, belongs to the
MFS class of proteins, and has signiﬁcant similarity to the
E. coli tetracycline transporter (TetA) [6], which has also 12-
membrane-spanning domains and also belong to MFS [11].
As shown in Fig. 5, some amino acid residues were conservedbetween TETRAN, Drtet and Tpo1p. These data suggest that
TETRAN is the human orthologue of Tpo1p.
3.5. Eﬀect of TETRAN on the sensitivity of cultured human cells
to NSAIDs
No biochemical and biological activities have been reported
for TETRAN. To characterize TETRAN, we obtained stable
transfectants of MKN45 (a human adenocarcinoma gastric
cell line) with an expression plasmid containing TETRAN
gene. This clone expressed about 2 times more TETRAN
mRNA than the control strains. This TETRAN-overexpress-
ing clone and control clone were incubated with various con-
centrations of indomethacin and the cell viability was
determined. As shown in Fig. 6A, the TETRAN-overexpress-
ing clone was more resistant to indomethacin than vector-
transfected cells. Furthermore, the TETRAN-overexpressing
clone was also resistant to diclofenac (Fig. 6B), suggesting that
overexpression of TETRAN in MKN45 cells makes cells resis-
tant to some NSAIDs.
Based on our previous report [12], we considered that cell
death seen in Fig. 6A and B is mediated by apoptosis, in other
words, overexpression of TETRAN makes cells resistant to
NSAID-induced apoptosis. For conﬁrming this point, we
examined the eﬀect of overexpression of TETRAN in
MKN45 cells on NSAID-induced apoptosis by counting cells
with apoptotic chromatin condensation. As shown in
Fig. 6C, treatment with indomethacin caused less apoptotic
cells in TETRAN-overexpressing clone than in control clone
(mock). Similar results were obtained with diclofenac
(Fig. 6C), suggesting that overexpression of TETRAN makes
cells resistant to NSAID-induced apoptosis. For further con-
ﬁrmation of this point, we used the siRNA for TETRAN.
Fig. 5. Amino acid sequences of human TETRAN, D. melanogaster Drtet, and S. cerevisiae TPO1. The alignment was performed by CLUSTAL W
from the Pole Bio-Informatique Lyonnais web server (* identical residues, : strongly similar residues, Æ weakly similar residues).
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MKN45 cells caused suppression of the mRNA expression of
TETRAN in its dose-dependent manner. Transfection of this
siRNA stimulated the apoptosis induced by indomethacin or
diclofenac (Fig. 7B), conﬁrming that expression of TETRAN
makes cells resistant to NSAID-induced apoptosis. The trasn-fection of this siRNA also elevated the background level of
apoptosis (without NSAIDs), suggesting that expression of
TETRAN also suppresses the spontaneous apoptosis under
the conditions.
We also examined the eﬀect of indomethacin on the expres-
sion of TETRAN mRNA in MKN45 cells. As shown in
0.9 mM
Indomethacin
0.7 mM
Diclofenaccontrol
0.9 mM
Indomethacin
0.7 mM
Diclofenaccontrol
A B
C
Fig. 6. Sensitivity to NSAIDs of human cells overexpressing
TETRAN. A stable transfectant of gastric carcinoma line MKN45
with the expression vector for TETRAN (closed square) and with the
vector only (open circle) were exposed for 38 h to the indicated
concentrations of indomethacin or diclofenac. Cell viability was
determined by the MTT method (A, B). Apoptotic cells with
condensed chromatins were counted and expressed relative to total
cells (C).Values are means ± S.E.M. (n = 6). *P < 0.05, ***P < 0.001.
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Fig. 7. Eﬀect of siRNA for TETRAN on NSAIDs-induced apoptosis.
MKN45 cells were transfected with indicated amounts (A) or 100 ng
(B) of siRNA for TETRAN (siTETRAN) or non-silencing siRNA
(NS) and cultured for 24 h. Cells were further incubated with or
without indicated concentration of indomethacin or diclofenac for 24 h
(B). The levels of TETRAN mRNA were estimated by real-time RT-
PCR experiments using a speciﬁc primer for each gene. Values were
normalized to actin gene expression and expressed relative to the
control sample (A). Apoptosis was monitored as described in the
legend of Fig. 6 (B). Values are means ± S.E.M. (n = 3). *P < 0.05,
***P < 0.001.
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mRNA in a dose-dependent manner. This induction probably
contributes to the protection of gastric cells from indometha-
cin.4. Discussion
Patients vary in sensitivity to the gastrointestinal side eﬀects
of NSAIDs, making clinical use diﬃcult. As the ﬁrst step to
understand this variation, we tried to identify genes that aﬀect
the direct cytotoxicity of NSAIDs, which may be at least partly
responsible for causing gastric ulcers [5]. In yeast, the TPO1
gene was shown to be involved in NSAID-resistance. It is
the ﬁrst such gene to be identiﬁed in yeast. We also identiﬁed
a possible human orthologue, TETRAN. Overexpression of
TETRAN or suppression of its expression by siRNA tech-
nique made cultured human cells resistant or sensitive, respec-
tively, to some NSAIDs. TETRAN is the ﬁrst protein shown
to aﬀect indomethacin resistance in human cells. In future, sin-
gle nucleotide polymorphism (SNP) analysis of TETRAN may
be important to understand the mechanism of variation of
patients for sensitivity to the gastrointestinal side eﬀects of
NSAIDs.
Tpo1p has putative12 membrane-spanning domains, be-
longs to the MFS class of proteins, and is located on plasma
membranes [13,14]. It was ﬁrst identiﬁed as a transporter for
polyamines [7,13], however, at present, it is thought to be amultidrug eﬄux pump, because its expression also caused
resistance to herbicides, cycloheximide, quinidine and immu-
nosuppressive drugs [9,15–17]. Therefore, Tpo1p is probably
involved in indomethacin export from yeast cells.
Based on the sequence similarity between TETRAN and
other drug eﬄux pumps, including Tpo1p, we consider that
TETRAN is probably an eﬄux pump for NSAIDs in human
cells. TETRAN’s amino acid sequence strongly suggests that
it also belongs to the MFS class of proteins [6]. Drug eﬄux
pumps can be separated into two groups based on the mode
of transport and energy source: primary and secondary active
transporters. Primary active transporters are also referred to as
ATP binding cassette (ABC) proteins, and use the energy of
ATP hydrolysis. Secondary active transporters, e.g. MFS class
proteins, act as anti-ports coupled with ion transport [18]. In
bacteria, secondary active transporters are predominant for
drug eﬄux [19], but in eukaryotic cells, primary active trans-
porters are predominant [20]. TETRAN is the ﬁrst MFS pro-
tein identiﬁed that is involved in drug resistance in human
cells, and further studies of such proteins will be important
to understand drug eﬄux mechanisms in human cells.
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